Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Return on Equity (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Return on Equity for 8 consecutive years, with 0.63% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity rose 21.0% to 0.63% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.63%, a 21.0% increase, with the full-year FY2024 number at 0.81%, down 31.0% from a year prior.
  • Return on Equity was 0.63% for Q3 2025 at Whitehawk Therapeutics, down from 0.5% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.32% in Q1 2021 to a low of 1.52% in Q3 2021.
  • A 5-year average of 0.61% and a median of 0.59% in 2023 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -179bps in 2021, then surged 107bps in 2022.
  • Whitehawk Therapeutics' Return on Equity stood at 0.77% in 2021, then skyrocketed by 52bps to 0.37% in 2022, then crashed by -59bps to 0.59% in 2023, then crashed by -78bps to 1.05% in 2024, then surged by 40bps to 0.63% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Return on Equity are 0.63% (Q3 2025), 0.5% (Q2 2025), and 0.44% (Q1 2025).